Shanghai MicroPort MedBot (Group) Co., Ltd. (HKG:2252)
 27.32
 -0.14 (-0.51%)
  Oct 31, 2025, 3:45 PM HKT
HKG:2252 Revenue
Shanghai MicroPort MedBot (Group) had revenue of 175.69M CNY in the half year ending June 30, 2025, with 269.07% growth. This brings the company's revenue in the last twelve months to 333.70M, up 113.60% year-over-year. In the year 2024, Shanghai MicroPort MedBot (Group) had annual revenue of 257.25M with 145.95% growth.
Revenue (ttm) 
 333.70M CNY
Revenue Growth 
 +113.60%
P/S Ratio 
 77.45
Revenue / Employee 
 753.28K CNY
Employees 
 443
Market Cap 
28.32B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 257.25M | 152.66M | 145.95% | 
| Dec 31, 2023 | 104.59M | 82.99M | 384.15% | 
| Dec 31, 2022 | 21.60M | 19.45M | 904.79% | 
| Dec 31, 2021 | 2.15M | - | - | 
| Dec 31, 2020 | - | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| JD Health International | 71.34B | 
| BeOne Medicines AG | 35.81B | 
| Sino Biopharmaceutical | 33.49B | 
| Alibaba Health Information Technology | 32.81B | 
| CSPC Pharmaceutical Group | 28.49B | 
| WuXi Biologics | 21.98B | 
| Hansoh Pharmaceutical Group Company | 14.45B | 
| Innovent Biologics | 12.52B |